期刊文献+

丹参软肝饮对肝纤维化大鼠肝功能及肾素-血管紧张素-醛固酮系统的影响 被引量:3

Influence of Danshen Ruangan Yin on Liver Fibrosis and RAAS of Rats
下载PDF
导出
摘要 目的观察丹参软肝饮对四氯化碳肝纤维化大鼠的治疗作用及其对血浆中肾素-血管紧张素-醛固酮系统(RAAS)的影响,探讨其抗肝纤维化的作用机制。方法除10只大鼠作为正常组外,其余用40%四氯化碳橄榄油皮下注射诱导肝纤维化模型,持续5周。分成模型组、依那普利组及丹参软肝饮高、中、低剂量组,给予相应的药物5周后,测定血清白蛋白(ALB)、谷氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、超氧化物歧化酶(SOD)、丙二醛(MDA)以及RAAS指标血管紧张素转化酶(ACE)、血浆肾素活性(PRA)、血管紧张素Ⅱ(AngⅡ)、醛固酮(ALD)。结果丹参软肝饮能够降低纤维化大鼠ALT、AST活性,提高ALB含量,升高SOD活性,降低MDA含量。与模型组比较,丹参软肝饮能显著降低ACE活性,降低ALD和AngⅡ水平,升高PRA。结论丹参软肝饮能改善四氯化碳肝纤维化大鼠的肝功能,并对其血浆中RAAS有一定的抑制作用。 Objective To observe the therapeutic effect of Danshen Ruangan Yin on hepatic fibrosis rats induced by CCh and its influence on renin-angiotensin-aldosterone system (RAAS), and to explore the antihepatofibrotic mechanism of Danshen Ruangan Yin. Methods Except 10 rats of normal control, other rats were induced by hypodermic injecting 40% CC14-olive oil mixture for 6 weeks to duplicate liver fibrosis, and then administrated with drugs based on groups (model, Enalapril, Danshen Ruangan Yin high, middle and low dosage) for 5 weeks. Serum ALB, ALT, AST, SOD, MDA, ACE, PRA, AngⅡ and ALD were detected. Results Danshen Ruangan Yin could decrease activity of ALT and AST, increase content of ALB, raise activity of SOD and depress content of MDA. Compared with model group, Danshen Ruangan Yin could decrease ACE, ALD and Ang Ⅱ significantly as well as increase PRA. Conclusion Danshen Ruangan Yin can improve liver function of hepatic fibrosis rats induced by CCh and inhibit plasma RAAS.
机构地区 浙江中医药大学
出处 《中国中医药信息杂志》 CAS CSCD 2011年第4期34-35,共2页 Chinese Journal of Information on Traditional Chinese Medicine
基金 浙江省自然科学基金(Y205335)
关键词 丹参软肝饮 肝纤维化 肾素-血管紧张素-醛固酮系统 大鼠 Danshen Ruangan Yin hepatic fibrosis RAAS rats
  • 相关文献

参考文献5

二级参考文献22

  • 1饶慧瑛,魏来.肝星状细胞的生物学特性及活化调控机制[J].世界华人消化杂志,2005,13(5):671-674. 被引量:24
  • 2杨志芳,毛飞,黄正明.肝纤维化的形成机制及治疗的研究进展[J].解放军药学学报,2006,22(2):129-132. 被引量:13
  • 3李萍,陶立坚,胡国龄,谭德明.1-(3-氟苯基)-5-甲基-2-(1H)吡啶酮对肝星状细胞的影响[J].中国临床药理学与治疗学,2007,12(7):782-785. 被引量:5
  • 4Albanis E,Friedman SL.Hepatic fibrosis.Pathogenesis and principles of therapy[J].Clin Liver Dis,2001,5(2):315-334.
  • 5Lamireau T,Desmouliere A,Bioulac-Sage P,et al.Mechanisms of hepatic fibrogenesis[J].Arch Pediatr,2002,9(4):392-405.
  • 6Van Eyken P,Sciot R,Desmet VJ,et al.Expression of the novel extracellular matrix component tenascin in normal and diseased human liver.An immunohisto-chemical stydy[J].J Hepatol,1990,11(1):42-52.
  • 7Kim T,Mars W,Stolz D,et al.Expression and activation of pro-MMP-2 and pro-MMP-9 during rat liver regeneration[J].Hepatology,2000,31(1):75-82.
  • 8Friedman SL.Molecular regulation of hepatic fibrosis,an integrated cellular response to tissue injury[J].J Biol Chem,2000,275:2247-2250.
  • 9Friedman SL,Arthur MJ.Activation of cultured rat hepatic lipocytes by kupffer cell conditioned medium.Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors[J].J Clin Invest,1989,84(6):1780-1785.
  • 10Burt AD.Cellular and molecular aspects of thepatic fibrosis[J].J Pathol,1993,170:105-114.

共引文献36

同被引文献35

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部